Navigation Links
Arbor Vita rapid H5N1 flu diagnostic presented at ICEID meeting
Date:3/27/2008

Sunnyvale, CA March 27, 2008 Preliminary research from the Department of Respiratory Disease Research at the Naval Health Research Center (NHRC) suggests that a rapid antigen assay test developed by Arbor Vita Corporation (AVC) shows promise as a useful diagnostic for the detection of the avian influenza virus in humans. Researchers from NHRC reported their findings last week at the 2008 International Conference on Emerging Infectious Diseases (ICEID) in Atlanta, Georgia.

The AVC test differs from other rapid-antigen assays in that it detects the NS1 protein, as opposed to the nucleoprotein (NP). Antigen capture is mediated through a PDZ protein, which binds the C-terminal region of the NS1 protein. As the C-terminal region of the NS1 protein differs for each influenza sub-type, a PDZ protein with high affinity to NS1 protein of H5 strains was chosen for assay development.

The format of the developed assay is the familiar lateral-flow rapid antigen assay. However, the role of the capture antibody is performed by a PDZ protein, which provides superior specificity and binding affinity. Lateral flow assays have several advantages that make them appealing for field deployment and far-forward mission use. These include: ease of use, time to results, cost, lack of cold-chain requirements and portability.

NHRCs archive of respiratory pathogens was used to evaluate the performance of the AVC avian influenza diagnostic against clinical samples. Two hundred samples from two years of surveillance were tested with the assay following procedures provided by AVC.

In addition, NHRC collaborated with Naval Medical Research Unit 3 (NAMRU3), located in Cairo, Egypt. NAMRU3, which is the WHO collaborating site for the African continent and Middle East region, has conducted surveillance for highly pathogenic avian influenza in wild and domestic birds, as well as human populations and has access to isolate H5N1 material. Twenty-eight different H5N1 isolates from avian and human sources were tested with the AVC assay. Results of the AVC assay were presented at ICEID that showed no false positives against the respiratory clinical panel. Of the 28 H5N1 cultures tested, 26 gave positive results on the assay (sensitivity = 93%).

The researchers concluded that the PDZ based assay produced by AVC shows promise as a useful diagnostic in our vigilance against avian influenza. The sensitivity of the assay towards avian strains is robust and the format of the test favors easy deployment. NHRC and NAMRU3 will continue to collaborate to evaluate this assay against other grown strains (H7, H9 etc.) as well as in actual outbreak situations.


'/>"/>

Contact: Debra Bannister
530-676-8001
Arbor Vita Corporation
Source:Eurekalert

Related biology news :

1. Coral reef fish harbor an unexpectedly high biodiversity of parasites
2. From brains to behavior: Cold Spring Harbor Protocols features methods for neuroscience research
3. Cold Spring Harbor Protocols highlights a method that captures cell growth and activity
4. Cold Spring Harbor Laboratorys lung cancer research program awarded $100,000 grant
5. Cold Spring Harbor Laboratory to play central role addressing key questions in plant biology
6. RNA-based methods for developmental studies are featured in Cold Spring Harbor Protocols
7. San Diego Harbor Police Deploy BIO-key(R) Automated Vehicle Location System
8. Popular apple variety harbors unusual cell growth
9. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
10. New decontamination system kills anthrax rapidly without lingering effects
11. New chemically-sensitive MRI scan may bypass some invasive diagnostic tests in next decade
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology: